Shares of Exelixis Inc. (EXEL) are soaring over 19% in pre-market today, after the company and Bristol Myers Squibb (BMY) announced that CheckMate -9ER, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) in combination with CABOMETYX (cabozantinib) compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma or RCC, met its primary endpoint of progression-free survival or PFS at final analysis, as well as the secondary endpoints of overall survival at a pre-specified interim analysis, and objective response rate.
from RTT - Before the Bell https://ift.tt/2RUpb8Z
via IFTTT
No comments:
Post a Comment